Table 1.
Characteristics of subsequent invasive cancers (any time after original screening round and up until follow-up) detected after atypia diagnosis
| Characteristics | All atypia | ADH or AIDEP | FEA | LISN | Mixed ductal and lobular |
|---|---|---|---|---|---|
| Women with atypia | 3238 | 1350‡ (41.7) | 403 (12.4) | 1101 (34.0) | 384 (11.9) |
| Women with subsequent breast cancer | 168 (5.2)* | 65 (4.8) | 13 (3.2) | 60 (5.4)* | 30 (7.8) |
| Subsequent breast cancer: invasive | 141† (83.9) | 54 (83.1) | 8 (61.5) | 54 (90.0) | 25† (83.3) |
| Site | |||||
| Ipsilateral cancer | 82 (58.2) | 29 (53.7) | 4 (50.0) | 32 (59.3) | 17 (68.0) |
| Contralateral cancer | 59 (41.8) | 25 (46.3) | 4 (50.0) | 22 (40.7) | 8 (32.0) |
| Grade | |||||
| 1 | 25 (17.7) | 9 (16.7) | 1 (12.5) | 8 (14.8) | 7 (28.0) |
| 2 | 69 (48.9) | 27 (50.0) | 5 (62.5) | 28 (51.9) | 9 (36.0) |
| 3 | 28 (19.9) | 15 (27.8) | 1 (12.5) | 7 (13.0) | 5 (20.0) |
| Unrecorded | 19 (13.5) | 3 (5.6) | 1 (12.5) | 11 (20.4) | 4 (16.0) |
| Size (mm) | |||||
| Median (interquartile range) | 15.0 (9.75-27.25) | 15.0 (10.0-24.75) | 14.0 (13.25-14.75) | 18.0 (10.0-30.0) | 12.0 (8.5-22.0) |
| ≤20 | 77 (54.6) | 35 (64.8) | 5 (62.5) | 23 (42.6) | 14 (56.0) |
| >20 to ≤50 | 32 (22.7) | 14 (25.9) | 0 | 13 (24.1) | 5 (20.0) |
| >50 | 7 (5.0) | 1 (1.9) | 1 (12.5) | 5 (9.3) | 0 |
| Unrecorded | 25 (17.7) | 4 (7.4) | 2 (25.0) | 13 (24.1) | 6 (24.0) |
| Nodal status | |||||
| 0 nodes positive | 84 (59.6) | 33 (61.1) | 5 (62.5) | 30 (55.6) | 16 (64.0) |
| 1, 2, or 3 nodes positive | 22 (15.6) | 12 (22.2) | 0 | 6 (11.1) | 4 (16.0) |
| >3 nodes positive | 7 (5.0) | 3 (5.6) | 2 (25.0) | 2 (3.7) | 0 |
| Unrecorded | 28 (19.9) | 6 (11.1) | 1 (12.5) | 16 (29.6) | 5 (20.0) |
| Hormone receptor status | |||||
| Oestrogen receptor positive | 108 (76.6) | 39 (72.2) | 7 (87.5) | 44 (81.5) | 18 (72.0) |
| Oestrogen receptor negative | 10 (7.1) | 8 (14.8) | 0 | 1 (1.9) | 1 (4.0) |
| Oestrogen receptor not known or unrecorded | 23 (16.3) | 7 (13.0) | 1 (12.5) | 9 (16.7) | 6 (24.0) |
| Progesterone receptor positive | 47 (33.3) | 14 (25.9) | 2 (25.0) | 21 (38.9) | 10 (40.0) |
| Progesterone receptor negative | 10 (7.1) | 5 (9.3) | 0 | 5 (9.3) | 0 |
| Progesterone receptor not known or unrecorded | 84 (59.6) | 35 (64.8) | 6 (75.0) | 28 (51.9) | 15 (60.0) |
| HER2 positive | 15 (10.6) | 5 (9.3) | 0 | 5 (9.3) | 5 (20.0) |
| HER2 negative | 89 (63.1) | 35 (64.8) | 5 (62.5) | 36 (66.7) | 13 (52.0) |
| HER2 not known or unrecorded | 37 (26.2) | 14 (25.9) | 3 (37.5) | 13 (24.1) | 7 (28.0) |
| Lymphovascular invasion | |||||
| Present | 12 (8.5) | 8 (14.8) | 0 | 3 (5.6) | 1 (4.0) |
| Possible | 3 (2.1) | 1 (1.9) | 0 | 2 (3.7) | 0 |
| Absent | 66 (46.8) | 29 (53.7) | 5 (62.5) | 23 (42.6) | 9 (36.0) |
| Not known or unrecorded | 60 (42.6) | 16 (29.6) | 3 (37.5) | 26 (48.1) | 15 (60.0) |
Data are numbers (%) unless indicated otherwise.
ADH=atypical ductal hyperplasia; AIDEP=atypical intraductal epithelial proliferation; FEA=flat epithelial atypia; HER2=human epidermal growth factor receptor 2; LISN=lobular in situ neoplasia.
*
An additional two women had recorded distant metastasis, but no breast cancer recorded.
†
This includes one woman with an invasive cancer recorded but no date of detection, who is therefore not included in the analysis of cancer rates at one, three, and six years after atypia diagnosis.
‡
This includes 326 (10.1%) women who received an AIDEP diagnosis.